Zoetis Inc.
ZTS · NYSE
Analyst Consensus
Hold
Analyst Ratings Synthesis
Consensus is Hold across 16 analysts. The supplied data gives a mean price target of $97, but the low and high targets are unavailable, so neither the target cluster nor the width of the target spread can be established. No named analyst or firm is identified as the most bullish or least bullish, and no target revisions or rating changes are reported for the past week. The substantive disagreement is therefore visible mainly in the earnings setup: expected earnings growth and possible support from companion-animal and international businesses versus U.S. competition, Librela concerns, and Zacks' view that the ingredients for a likely beat are lacking.
- USANA Health Sciences (USNA) Reports Q2 Loss, Lags Revenue Estimates
- Gear Up for Zoetis (ZTS) Q2 Earnings: Wall Street Estimates for Key Metrics
- ZTS Set to Report Q2 Earnings: Here's What Investors Should Expect
- Neogen Reports Narrower Loss In Q4 And FY26, Advances Petrifilm Manufacturing
- Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth
Rating Actions
No individual rating actions have been captured for ZTSyet. Consensus figures above come from Nasdaq's aggregate feed.
